Current treatments for GPP patients include granulocyte/monocyte apheresis and anti-TNF (Fujisawa et al., 2015; Koike et al., 2017) suggesting that Card14LSL-E138A/LSL-E138ARosa26CreERT2/+ mice could be used for pre-clinical testing of new medicines for GPP treatment. The gene discussed is TNF; the disease is psoriasis 14, pustular.